Technical Analysis for KRYS - Krystal Biotech, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -0.88% | |
| 50 DMA Resistance | Bearish | -0.88% | |
| 200 DMA Support | Bullish | -0.88% | |
| Multiple of Ten Bearish | Other | -0.88% | |
| Up 3 Days in a Row | Strength | -0.88% | |
| MACD Bearish Centerline Cross | Bearish | -0.74% | |
| 200 DMA Support | Bullish | -0.74% | |
| NR7 | Range Contraction | -0.74% | |
| NR7-2 | Range Contraction | -0.74% | |
| Crossed Above 200 DMA | Bullish | 0.51% |
| Alert | Time |
|---|---|
| Down 1% | 22 minutes ago |
| 20 DMA Resistance | 43 minutes ago |
| Rose Above 20 DMA | about 1 hour ago |
| Up 1% | about 1 hour ago |
| 20 DMA Resistance | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/04/2024
Krystal Biotech, Inc. Description
Krystal Biotech, Inc. gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Compnay's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Compnay's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, dehydration and stunted growth.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Clinical Development Inflammation Rare Diseases Gene Therapy Genetic Diseases Genodermatoses Herpes Epidermolysis Bullosa Dehydration Herpes Simplex Netherton Syndrome Herpes Simplex Virus Skin Inflammation Dermatological Diseases Ichthyosis Itchiness
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 219.34 |
| 52 Week Low | 99.135 |
| Average Volume | 239,145 |
| 200-Day Moving Average | 174.65 |
| 50-Day Moving Average | 180.03 |
| 20-Day Moving Average | 179.42 |
| 10-Day Moving Average | 183.21 |
| Average True Range | 7.98 |
| RSI (14) | 48.19 |
| ADX | 15.81 |
| +DI | 26.22 |
| -DI | 24.76 |
| Chandelier Exit (Long, 3 ATRs) | 183.91 |
| Chandelier Exit (Short, 3 ATRs) | 187.59 |
| Upper Bollinger Bands | 194.47 |
| Lower Bollinger Band | 164.38 |
| Percent B (%b) | 0.46 |
| BandWidth | 16.77 |
| MACD Line | -0.20 |
| MACD Signal Line | 0.38 |
| MACD Histogram | -0.587 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 190.15 | ||||
| Resistance 3 (R3) | 190.01 | 185.85 | 188.15 | ||
| Resistance 2 (R2) | 185.85 | 182.78 | 185.92 | 187.48 | |
| Resistance 1 (R1) | 181.98 | 180.88 | 183.91 | 182.12 | 186.81 |
| Pivot Point | 177.81 | 177.81 | 178.78 | 177.89 | 177.81 |
| Support 1 (S1) | 173.94 | 174.74 | 175.88 | 174.08 | 169.39 |
| Support 2 (S2) | 169.78 | 172.85 | 169.85 | 168.72 | |
| Support 3 (S3) | 165.90 | 169.78 | 168.05 | ||
| Support 4 (S4) | 166.05 |
